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Background: Schizophrenia is a severe mental disorder that is characterized not only 
by symptomatic severity but also by high levels of functional impairment. An evaluation of 
clinical outcome in treatment of schizophrenia should therefore target not only assessing 
symptom change but also alterations in functioning. This study aimed to investigate 
whether there is an agreement between functional- and symptom-based outcomes in a 
clinical sample of admissions with chronic forms of schizophrenia.
Methods: A full 3-year cohort of consecutive inpatient admissions for schizophrenia 
(N = 205) was clinically rated with the Positive and Negative Symptom Scale (PANSS) 
and the Health of the Nation Outcome Scales (HoNOS) as measures of functioning at 
the time of admission and discharge. The sample was stratified twofold: first, accord-
ing to the degree of PANSS symptom improvement during treatment with the sample 
being divided into three treatment response groups: non-response, low response, and 
high response. Second, achievement of remission was defined using the Remission in 
Schizophrenia Working Group criteria based on selected PANSS symptoms. Repeated 
measures analyses were used to compare the change of HoNOS scores over time 
across groups.
results: More than a half of all admissions achieved a symptom reduction of at least 
20% during treatment and around one quarter achieved remission at discharge. Similarly, 
HoNOS scores improved significantly between admission and discharge. Interaction 
analyses indicated higher functional improvements to be associated with increasing 
levels of treatment response.
conclusion: Functional improvement in individuals treated for schizophrenia was linked 
to a better clinical outcome, which implies a functional association. Thus, improvement of 
functioning represents an important therapeutic target in the treatment of schizophrenia.
Keywords: schizophrenia, functioning, treatment outcome, health of the nation Outcome scales, Positive and 
negative symptom scales
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inTrODUcTiOn
The Health of the Nation Outcome Scales (HoNOS) (1, 2) have 
gained increasing attention as general measures for treatment 
outcome in psychiatric settings (3). The HoNOS were developed 
to provide brief, accurate, and relevant measures of overall mental 
health and social functioning for clinical practice (1). A growing 
body of evidence suggests that the HoNOS are related to illness 
severity (4, 5), overall clinical pre–post change (4, 6), overall 
symptom improvement, and a history of treatment utilization (7), 
as well as the length of hospital stay (8). However, the HoNOS 
seem to perform differently across the diagnostic spectrum (9, 
10). In fact, earlier findings from our study showed that schizo-
phrenic psychotic disorders, compared to other common mental 
disorders, were related to poorer HoNOS baseline levels (11), as 
well as to only marginal change over time (12). Despite an over-
representation of chronic and schizophrenia patients in the devel-
opment and validation studies of the HoNOS (13), evidence for 
the usefulness of the HoNOS as a measure for functional change 
in outcome monitoring of schizophrenic patients in relation to 
psychosis-specific measures is still rare.
In many aspects, schizophrenia can be described as a poor 
outcome disorder (14). So far, there is no universally accepted 
definition of remission for schizophrenia; but, however, there is 
a broad consensus that not only symptom improvement but also 
a reduction of functional impairment should be considered (15, 
16). Actually, it can be assumed that symptomatic and functional 
improvement is functionally related to patients with schizophre-
nia (17). An operationalization of remission was proposed by 
the Remission in Schizophrenia Working Group (RSWG) (18) 
based on temporal and severity criteria. Although this definition 
has been used in a number of clinical trials, level and course of 
functioning were not part of this definition.
Therefore, the current study aimed to fill this gap by exploring 
whether the level of symptomatic treatment response between 
admission and discharge as well as remission status was system-
atically linked to change of functioning in a sample of inpatients 
with chronic schizophrenia. For this purpose, we examined 
whether either the level of symptomatic improvement (treatment 
response) or meeting remission criteria according to the Positive 
and Negative Symptom Scale (PANSS) was linked to an overall 
functional improvement as measured by the HoNOS.
MaTerials anD MeThODs
sample and Procedure
The Center for Integrative Psychiatry [ZIP (German): Zentrum 
für Integrative Psychiatrie], as part of the Psychiatric University 
Hospital of Zurich, is a specialist unit for the treatment of “heavy-
users,” i.e., those patients with frequent and/or long-term hospi-
talizations for whom outpatient treatment is often insufficient to 
prevent relapse (19, 20).
Our study sample consists of a full 3-year cohort of consecutive 
inpatient admissions referred to our center for treatment between 
June 1, 2012 and June 30, 2015. All patients who were diagnosed 
with a schizophrenic psychosis according to the WHO ICD-10 
(21) (N = 216) diagnostic criteria were considered for the current 
study. Patients with treatment duration shorter than 7  days 
(N = 11) were excluded to avoid overlap since ratings at discharge 
require a minimal retrospective observation period of 7 days.
Treatment followed an integrative approach in accordance 
with current treatment guidelines, including psychopharmaco-
logical and psychotherapeutic treatment, as well as psychosocial 
interventions (22–24). Treatment programs were individually 
adapted to the patients’ symptomatic load and level of func-
tional impairment. The study was approved by the local Ethics 
Committee of the Canton of Zurich, Switzerland.
raters and Training
Raters were clinicians, i.e., either psychiatrists or psychiatry resi-
dents or clinical psychologists. All raters were trained in specific 
workshops on the use and objectives of the measures used in the 
study. The workshops followed a standardized schedule, using 
case vignettes and video examples. Refresher training sessions 
were provided on a regular basis, at least twice a year, with train-
ers being available for consultation at any time. On all measures, 
information was rated retrospectively for the 7  days prior to 
admission and again for the 7 days prior to discharge. All relevant 
information was derived from either the admission and discharge 
interviews or directly by behavioral observation, while additional 
information was provided by the nursing staff, social workers, 
and significantly others.
Measures
Positive and Negative Symptom Scale
The PANSS is a semistructured interview that was designed to 
measure symptom severity in individuals with a psychotic dis-
order, in particular schizophrenia and schizoaffective disorder 
(25, 26). The PANSS consists of 30 items with 3 subscales for 
the domains of positive (7 items), negative (7 items), and non-
specific symptoms (16 items), although only the total score was 
considered for the current study. Each symptom item is rated on 
a 7-point Likert scale response format from 1 (non-present) to 7 
(very severe), with a possible range from 30 to 210 (25).
Treatment Response
Treatment response was defined by the degree of symptom 
improvement according to the PANSS, following the criteria used 
in psychopharmacological trials (27, 28), with a symptom reduc-
tion of 20 or 50% of the initial PANSS score used as a cutoff to 
define response (28–30). In order to obtain an appropriate meas-
ure of relative change, the PANSS was transformed beforehand 
into a ratio scale by subtracting 30 points from the total score (31). 
Accordingly, the study sample was assigned into three groups of 
treatment response: (1) high response (HR): those patients who 
had a ≥50% reduction of the PANSS total score between admis-
sion and discharge; (2) low response (LR): those patients who 
had a reduction between 20 and 49% of the PANSS total score; 
and (3) non-response (NR): those patients who showed a change 
lower than 20%.
Remission Status
Patients were classified as remitted (REM) according to the 
Remission in Schizophrenia Working Group criteria (RSWGcr) 
(18), when all of the following eight PANSS items, delusions, 
TaBle 1 | Overview of sample characteristics.
study sample  
(N = 205) 
column% / M ± sD
Sex Male 61.0
Female 39.0
Age 40.2 ± 12.2
Civil status Single 66.3
Married 19.0
Divorceda 14.6
Education No compulsory school 15.1
Compulsory school degree 18.5
Skilled worker 35.1
Secondary/vocational school degree 12.7
University degree 2.9
N/A 15.6
Number of previous  
admissions to our unit
No previous admissions 59.0
1 20.0
2 8.3
3 or more 12.7
Duration of treatment  
(in days)
≤14 days 10.2
15–30 days 14.2
31–60 days 28.8
>60 days 46.8
aIncluding N = 1 subject that was widowed.
TaBle 2 | agreement between level of treatment response and remission 
status according to the Panss in the study sample.
level of treatment response
nr 
n(%)
lr 
n(%)
hr 
n(%)
Total 
n(%)
remission 
status
noreM 81 (89.0) 49 (74.2) 22 (45.8) 152 (74.2)
reM 10 (11.0) 17 (25.8) 26 (54.2) 53 (25.9)
Total 91 (100.0) 66 (100.0) 48 (100.0) 205 (100.0)
NR, non-response; LR, low-response; HR, high-response; NoREM, no remission; REM, 
remission.
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conceptual disorganization, hallucinatory behavior, blunted 
affect, social withdrawal, lack of spontaneity, mannerisms pos-
turing, and unusual thought content, were rated as mild or less 
severe (i.e., score ≤3 points) at discharge. Otherwise, a patient 
was classified as non-remitted (NoREM) (18).
Health of the Nation Outcome Scales
The HoNOS are observer-rated scales and comprise 12 domains 
of functioning (aggressiveness; non-accidental self-injury; prob-
lem drinking or drug taking; cognitive problems; physical illness 
or disability; hallucinations and delusions; depressed mood; 
other mental and/or behavioral problems; problems with rela-
tionships; problems with activities of daily living; problems with 
living conditions; and problems with occupation and activities). 
Each scale can be rated from 0 (no problem) to 4 (severe/very 
severe problems). Thereby, scores of ≥2 are considered clinically 
significant (1, 32). All 12 ratings can be summed up to a total 
score, whereof a minimum number of 9 responses were strongly 
recommended for generating a total score (33).
statistical analyses
Descriptive statistics are provided to characterize the study sample 
regarding demographic features and treatment-related variables 
(Table 1). Chi-square tests were conducted to examine the agree-
ment between treatment response and remission status (Table 2). 
Distributions of PANSS and HoNOS scores (means ± standard 
deviations) at the time of admission and discharge are provided 
for the total sample as well as stratified by level of treatment 
response and remission status (Table  3). One-way analyses of 
variance (ANOVA) and Bonferroni post hoc group comparisons 
were conducted to test for group differences either at admission 
or at discharge. Repeated measures ANOVAs, separately for the 
PANSS and HoNOS, were conducted to examine whether scores 
changed over time, i.e., from admission to discharge. These 
analyses were repeated and time-by-group interaction terms were 
added for both levels of treatment response and remission status. 
In case of significant interaction effects, interaction contrasts 
were specified to examine group differences for change.
All analyses were conducted using STATA, SE, 12th edition (34).
resUlTs
Our study sample consists of N  =  205 inpatient admis-
sions for schizophrenic psychosis (39.0% females; mean 
age =  40.2 ±  12.2  years; range =  17–69). The majority of the 
sample was single (66.3%), had finished compulsory school 
(18.5%), worked in a skilled job (35.1%), had their first admis-
sion to our institution (59.0%), and received treatment for more 
than 60 days (46.8%). For more detailed information on sample 
characteristics, see Table 1.
According to the degree of change in the PANSS total score 
from admission to discharge, N = 48 (23.4%) were assigned as 
high responders (HR), N = 66 (32.2%) as low responders (LR), 
and N = 91 (44.4%) as non-responders (NR) (Table 2). According 
to the remission criteria (18), around one-quarter (25.9%; N = 53) 
achieved remission (REM) at discharge and N = 152 (74.2%) did 
not (NoREM). The duration of treatment was significantly linked 
to treatment response (F2,202 = 10.29; p < 0.001) but not to remis-
sion status (F1,203 =  3.15; n.s.). Accordingly, the mean duration 
of treatment in NR was 51.7 (±42.5) days, in LR 70.3 (±44.5) 
days, and 88.8 (±56.1) days in HR. Pairwise group comparisons 
revealed HR and LR to differ significantly from NR but not from 
each other (not tabulated).
Despite different criteria, both level of treatment response 
and remission status were significantly associated (χ2 =  30.56; 
df = 2; p < 0.001). Accordingly, more than the half from HR also 
achieved REM compared to only one quarter from LR and about 
11% from NR, respectively.
Table 3 displays distributions of PANSS and HoNOS scores at 
admission and baseline for the total sample as well as stratified by 
either level of treatment response or remission status.
Subsamples of either treatment response or remission status 
significantly differed in their initial PANSS scores at admission 
and at discharge (Table 3). HR had the highest baseline scores, 
followed by LR and, at lowest level, by NR but the difference 
between HR and LR was not statistically significant. At discharge, 
NR had the highest scores, at a similar level to those at admission; 
LR had lower scores than at admission; and finally, HR had the 
FigUre 1 | interaction plot: change in honOs between admission and 
discharge by level of treatment response.
TaBle 3 | admission and discharge Panss and honOs scores for the total sample as well as subgroups of treatment response level and remission 
status: group comparisons and repeated measures anOVa for change over time for the total sample and by subgroup levels.
Panss honOs
study sample admission 
M ± sD
Discharge 
M ± sD
Test for change  
Ffactor(df(term),df(residual))
admission 
M ± sD
Discharge 
M ± sD
Test for change  
Ffactor(df(term),df(residual))
Total 99.7 ± 26.9 82.3 ± 26.9 Ftime(1,204) = 82.34*** 22.4 ± 7.3 16.0 ± 7.5 Ftime(1,203) = 164.42***
level of treatment response
NR 93.2 ± 26.3 98.8 ± 27.0 Ftime(1,202) = 380.79*** 21.4 ± 7.7 19.1 ± 8.1 Ftime(1,201) = 318.22***
LR 104.3 ± 25.6 77.6 ± 16.3 Ftime-by-group(2,202) = 185.19*** 23.6 ± 7.6 16.0 ± 5.9 Ftime-by-group(2,201) = 53.10***
HR 105.6 ± 27.7 57.4 ± 13.2 Interaction contrasts: HR vs.  
NR***; LR vs. NR***; HR vs. LR***
22.8 ± 6.1 10.2 ± 4.2 Interaction contrasts: HR vs. 
NR***; LR vs. NR***; HR vs. LR***
p-Value for group 
differences
0.008 <0.001 0.155 <0.001
Post hoc group 
comparisons
NR < LR, HR HR < LR < NR – HR < LR < NR
remission status
NoREM
REM
104.8 ± 24.3
84.9 ± 28.7
91.4 ± 24.5
56.3 ± 12.6
Ftime(1,203) = 97.81*** 23.8 ± 7.1
18.4 ± 6.6
17.9 ± 7.2
10.7 ± 5.5
Ftime(1,202) = 145.03***
Ftime-by-group(1,203) = 12.68*** Ftime-by-group(1,202) = 2.47 n.s.
Interaction contrasts: NoREM vs. 
REM***
p-Value for group 
differences
<0.001 <0.001 <0.001 <0.001
PANSS, Positive and Negative Symptom Scales; HoNOS, Health of the Nation Outcome Scales; NR, non-response; LR, low-response; HR, high-response; NoREM, no remission; 
REM, remission; n.s., not significant.
***p < 0.001.
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lowest scores at discharge; all differences were statistically signifi-
cant. Regarding remission status, those who achieved remission 
at discharge had significantly lower PANSS scores at baseline 
and discharge than those who did not achieve remission. PANSS 
scores significantly decreased between admission and discharge 
in the total sample. However, interaction analyses revealed 
that this change was highly group-specific for both treatment 
response and remission status. Interaction contrasts indicated 
PANSS scores to decrease more steeply in low- and even more 
in HR compared to NR, as well as in REM compared to NoREM.
Regarding the HoNOS, no significant differences between lev-
els of treatment response were found at admission. At discharge, 
all groups differed significantly from each other, with highest 
scores in NR followed by LR and HR with lowest scores. Overall, 
HoNOS scores significantly decreased over time. Interaction 
analyses revealed that change in HoNOS score significantly 
differed between treatment response groups. Contrast analyses 
indicated that the higher the response level (i.e., from LR to HR), 
the steeper the decrease was in HoNOS scores between admission 
and discharge (Figure 1). Finally, REM at discharge was linked to 
significantly lower HoNOS scores at baseline and discharge than 
NoREM. However, the change in HoNOS scores over time was 
not linked to remission status.
From demographic factors and treatment-related variables, 
only the duration of stay (F3,200 = 5.38; p = 0.001) was linked to 
a change in HoNOS over time (i.e., interaction with time), while 
demographic factors were all unrelated (not tabulated). Therefore, 
the duration of stay was included in the model as an additional 
factor to the level of treatment response but, however, revealed 
no additional significant interaction with time (F3,198 = 1.62; n.s.).
DiscUssiOn
Our results revealed an overall high symptom load and functional 
impairment in our study sample, which supports general sugges-
tions of a high clinical severity of schizophrenia (26). An overall 
symptomatic and functional improvement was apparent between 
admission and discharge, which far exceeded a half standard 
deviation, indicating a clinically relevant change (35). More than 
a half of the sample achieved a symptom reduction of at least 
20% during their stay, while around one quarter was considered 
as REM on discharge from our hospital. The overall observed 
5Egger et al. HoNOS as Outcome Measures in Schizophrenia
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improvement in our study sample is in line with the reported 
improvement in patients with chronic schizophrenia (36, 37).
Both level of treatment response and remission status showed a 
certain level of agreement; nevertheless, they differed with respect 
to symptom severity and functioning cross-sectionally as well as 
over time. Although baseline functioning was comparable across 
levels of treatment response, those with substantial response (LR 
and HR) were linked to higher initial symptom severity than NR 
and were each related to greater improvement and better outcome 
at discharge than lower levels of treatment response. This observa-
tion is in line with recent findings, suggesting that those with higher 
initial PANSS scores tend to have a more positive outcome (38, 39).
Our findings demonstrate that baseline symptomatology 
largely affects symptom course over time. However, it has also been 
suggested that those with lower baseline severity required smaller 
symptom reductions to achieve a psychometrical improvement, 
which limits the usefulness of the change in PANSS as a primary 
outcome measure (28, 40). For this reason, it might be useful to 
accomplish outcome monitoring by standardized remission cri-
teria in order to enhance the definition of clinical change (3, 11). 
Indeed, we could demonstrate that those who met the definition 
of remission according to RSWGcr (18) at discharge had lower 
total PANSS scores at discharge than non-remitters but, however, 
also lower baseline scores. This might explain why remitters did 
not show specific improvement in their functioning compared to 
non-remitters; it rather seems that they had lower severity and 
impairment already at baseline.
Finally, our findings further suggest that functional improve-
ment over the time of treatment was indeed related to treatment 
duration but, however, not in addition to treatment response. 
This can be explained by the high association between level of 
treatment response and treatment duration, suggesting that 
there might be a functional relationship. Thus, although appar-
ently linked to functional improvement, the length of treatment 
seems to become secondary in relation to symptomatic change. 
The missing association between the number of previous 
hospitalizations and subsequent functional change seems to 
contradict previous findings that suggested that patients with 
chronic schizophrenia generally tend to have poorer outcomes 
than first-episode patients (41), but since our data were limited 
to previous admissions to our institution, true effects might be 
underestimated or even concealed.
In sum, our findings provide strong evidence for a functional 
relationship between the degree of symptomatic change and the 
course of functioning during clinical treatment for schizophrenic 
psychosis. Patients with higher initial clinical severity seem to 
benefit more from treatment, i.e., they have more potential for 
clinical improvement (39). We further showed that remission as 
it was defined in our study did not warrant functional improve-
ment. This would be in line with previous observations that 
improvement in functioning or other relevant areas sometimes 
occurs independently from symptom remission and is often more 
important for recovery than the latter (16, 42–46).
Nevertheless, this study suffers from several limitations that 
have to be acknowledged. First of all this study is based on a 
fairly small number of cases, especially in the HR group (N = 48). 
Second, our sample is based on admission data rather than on 
patients. Therefore, we cannot rule out that some patients may 
have been admitted multiple times during the study period and 
are therefore included more than once, even in different subsam-
ples. Third, the required RSWGcr time criterion was not applied 
due to missing follow-up observations, which, however, was the 
usual approach in a large number of studies (47). And finally, 
we did not include self-report measures in the current study. 
Thus, we cannot conclude whether the change observed by the 
clinical raters was also subjectively experienced by the individuals 
themselves (27, 48). This, however, will be the subject of future 
investigations.
In conclusion, the findings of our study broadly contribute to 
the existing literature with regard to treatment outcome moni-
toring in patients with schizophrenia. We could demonstrate 
that higher initial clinical severity was associated with better 
treatment outcome. However, we showed that an improvement 
of psychotic symptoms, but not remission, was necessarily associ-
ated with better functioning due to different baseline severity of 
illness. Therefore, it appears reasonable and appropriate to use 
multiple scales for the assessment of clinical outcomes in specific 
patient groups (3, 49).
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